
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
Major initiatives to expand healthcare coverage to the uninsured or reform Medicaid are low on the priority list at the Bush White House.






